Agency
Renew Counseling Center of NC LLC
Renew Counseling Center of NC LLC was paid $8.17M by Medicaid between Jan 2018 and Dec 2024, across 22 billing codes. Its largest line is 90837, psychotherapy session, about an hour — 34% of everything it billed.
33Billing provider infoRENEW COUNSELING CENTER OF NC LLC
FAYETTEVILLE, NC 28304
FAYETTEVILLE, NC 28304
33aNPI1528470325assigned 05/28/2014
33bProvider typeCommunity/Behavioral Health Agency
28Total paid$8.17M
24GClaims105,258
24DCodes billed22
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Community/Behavioral Health Agency providers in North Carolina
Rank by total paid#104 of 856
Median peer was paid$908K
This provider vs. median9.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,395 | $544K | |
| 2019 | 10,610 | $834K | |
| 2020 | 13,637 | $1.07M | |
| 2021 | 21,731 | $1.55M | |
| 2022 | 26,914 | $1.74M | |
| 2023 | 16,627 | $1.54M | |
| 2024incomplete | 9,344 | $889K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 34% | 33,591 | 12,317 | $2.75M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 16,934 | 10,903 | $1.33M |
| H0038 | Self-help/peer services, per 15 minutes | 12% | 11,877 | 1,622 | $984K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 11% | 5,552 | 3,740 | $906K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.9% | 11,683 | 7,081 | $724K |
| T1017 | Case management, billed per 15 minutesTargeted case management, each 15 minutes | 4.2% | 1,294 | 876 | $345K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.0% | 4,101 | 2,387 | $246K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.4% | 6,649 | 3,952 | $199K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.0% | 1,696 | 967 | $166K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.5% | 2,199 | 1,188 | $122K |
| 99205 | Prolong outpt/office vis | 1.1% | 544 | 495 | $87K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.0% | 3,979 | 2,282 | $82K |
10 more codes
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,379 | $59K |
| 99401 | <1% | 2,071 | $59K | |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 339 | $45K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 352 | $39K |
| 80305 | <1% | 688 | $8K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 87 | $7K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 88 | $4K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 44 | $4K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 93 | $2K |
| 90785 | <1% | 18 | $45.78 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNEGRON, NORMA (DIRECTOR OF OPERATIONS)